CHMP recommends EU approval of Roche's Avastin for platinum-resistant recurrent ovarian cancer

Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve the use of Avastin (bevacizumab) in combination with chemotherapy as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy. Ovarian cancer has the highest mortality rate of all gynaecological cancers.1 Of the 230,000 women diagnosed worldwide each year many will have advanced disease that will return after initial treatment.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news